Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
Thyroid® · 2024-05 · 34 (5) · 541-558
DOI: 10.1089/thy.2023.0642 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Thyroid®, online erschienen am 24.05.2024. Verfasst von Jacob Hampton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Services, John Hunter Hospital, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Cancer Survivors, Fear, Neoplasm Recurrence, Local, Quality of Life. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite excellent survival rates, health-related quality of life detriments are common in differentiated thyroid cancer survivors and can be driven by fear of cancer recurrence (FCR). This review aims to report the incidence of FCR in thyroid cancer survivors and synthesize evidence regarding contributing factors. An overview and appraisal of the range of tools used to measure FCR is presented.
Methods
A systematic review of the English literature was performed. The search across six electronic databases generated 3414 studies. Two reviewers independently screened the citations and full-text articles, of which 31 were included. The data were extracted independently by two reviewers.
Results
The incidence of FCR was reported in 27/31 studies and ranged from 15% to 91%. Direct comparisons regarding incidence and severity of FCR were not possible due to heterogeneity in cut-points used to define FCR. A total of eight validated tools were used to measure FCR across all studies, with five studies using self-developed nonvalidated items. There was minimal repetition of validated tools and no clear consensus as to a preferred survey tool. Factors influencing FCR were reported in 11 studies. There was minimal overlap of factors influencing FCR. Risk factors contributing to increased FCR reported in more than one study included young age and an upcoming clinical appointment. Male gender and higher education levels were reported in more than one article as protective. No literature evaluating interventions to address FCR in thyroid cancer survivors was found.
Conclusion
FCR is common in thyroid cancer survivors, but significant heterogeneity in the current evidence base limits assessment of incidence, severity, or risk factors. There is a need to use validated tools to assess FCR in both research and clinical contexts. Reliable assessment of FCR may permit routine assessment of FCR in clinical practice and allow interventions to be prospectively evaluated to optimize the holistic well-being of thyroid cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgical Services, John Hunter Hospital, Newcastle, New South Wales, Australia.
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
- Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
- Department of Endocrinology, John Hunter Hospital, Newcastle, New South Wales, Australia.
ORCID-Profile: Jacob Hampton, Christine J O'Neill
Zitieren
APA
Hampton, J., Alam, A., Zdenkowski, N., Rowe, C., Fradgley, E., & O'Neill, C. J. (2024). Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review. Thyroid®, 34(5), 541-558. https://doi.org/10.1089/thy.2023.0642
Vancouver
Hampton J, Alam A, Zdenkowski N, Rowe C, Fradgley E, O'Neill CJ. Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review. Thyroid®. 2024;34(5):541-558. doi:10.1089/thy.2023.0642
BibTeX
@article{Hampton2024,
author = {Hampton, Jacob and Alam, Ahmad and Zdenkowski, Nicholas and Rowe, Christopher and Fradgley, Elizabeth and O'Neill, Christine J},
title = {Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review},
journal = {Thyroid®},
year = {2024},
volume = {34},
number = {5},
pages = {541--558},
doi = {10.1089/thy.2023.0642}
}
EUVIMED